Results 101 to 110 of about 15,932 (195)

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim   +7 more
wiley   +1 more source

Dapagliflozin [PDF]

Drugs in R & D, 2010
openaire   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve

Internal Medicine Journal, EarlyView.
Abstract Background Sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) improve symptoms, reduce hospitalisations and increase survival in patients with heart failure with reduced ejection fraction (HFrEF). This study evaluated SGLT2i prescribing compliance in hospitalised patients with HFrEF at an Australian tertiary hospital.
Salim Memon, Kanishaa Subhaharan, Tasnuba Ashan, Rogges Anandarajah, Nuwan Jasenthu Kankanamage   +4 more
wiley   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, EarlyView.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

Dapagliflozin effect on anemia outcomes in patients with diabetes and CKD

Future Journal of Pharmaceutical Sciences
Background Anemia is a prevalent complication in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), contributing to adverse clinical outcomes.
Ramy Ibrahim Elwaraky, Amira B. Kassem, Ahmed Fathi Elkeraie, Gamal Abdelhay Omran, Noha A. El‑Bassiouny   +4 more
doaj   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials

Diabetes, Obesity and Metabolism, EarlyView.
Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐Ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon, In Kyung Jeong   +10 more
wiley   +1 more source